These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 16162020)

  • 21. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia.
    Aspa J; Rajas O; de Castro FR
    Expert Opin Pharmacother; 2008 Feb; 9(2):229-41. PubMed ID: 18201146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monotherapy versus Combination Therapy in Patients Hospitalized with Community-Acquired Pneumonia.
    Kolditz M; Halank M; Höffken G
    Treat Respir Med; 2006; 5(6):371-83. PubMed ID: 17154666
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Guiding Principles for the use of Fluroquinolones in Out-patient Community Settings of India: Panel Consensus.
    Vora A; Krishnaprasad K
    J Assoc Physicians India; 2017 Aug; 65(8):51-52. PubMed ID: 28799307
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fluoroquinolones in community-acquired pneumonia: guide to selection and appropriate use.
    Frei CR; Labreche MJ; Attridge RT
    Drugs; 2011 Apr; 71(6):757-70. PubMed ID: 21504252
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Empiric therapy of community-acquired pneumonia: a transatlantic controversy].
    Garin N; Nendaz M
    Rev Med Suisse; 2006 Jan; 2(50):289-90, 292-4. PubMed ID: 16503046
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The clinical efficacy of fluoroquinolone and macrolide combination therapy compared with single-agent therapy against community-acquired pneumonia caused by Legionella pneumophila.
    Nakamura S; Yanagihara K; Izumikawa K; Seki M; Kakeya H; Yamamoto Y; Senjyu H; Saito A; Kohno S
    J Infect; 2009 Sep; 59(3):222-4. PubMed ID: 19592113
    [No Abstract]   [Full Text] [Related]  

  • 27. [Comparison of the combination and quinolone therapy in community acquired pneumonia].
    Kılıç Soylar Ö; Kılınç O; Ellidokuz H
    Tuberk Toraks; 2015 Sep; 63(3):165-9. PubMed ID: 26523897
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Monotherapy versus dual therapy for community-acquired pneumonia in hospitalized patients.
    Martinez FJ
    Clin Infect Dis; 2004 May; 38 Suppl 4():S328-40. PubMed ID: 15127366
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fluoroquinolones or macrolides in combination with β-lactams in adult patients hospitalized with community acquired pneumonia: a systematic review and meta-analysis.
    Vardakas KZ; Trigkidis KK; Falagas ME
    Clin Microbiol Infect; 2017 Apr; 23(4):234-241. PubMed ID: 27965070
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antibiotic treatment strategies for community-acquired pneumonia in adults.
    Postma DF; van Werkhoven CH; van Elden LJ; Thijsen SF; Hoepelman AI; Kluytmans JA; Boersma WG; Compaijen CJ; van der Wall E; Prins JM; Oosterheert JJ; Bonten MJ;
    N Engl J Med; 2015 Apr; 372(14):1312-23. PubMed ID: 25830421
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
    Segreti J; House HR; Siegel RE
    Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Empiric therapy of community-acquired pneumonia: guidelines for the perplexed?
    Cunha BA
    Chest; 2004 May; 125(5):1913-9. PubMed ID: 15136407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Diagnosis and management of community-acquired pneumonia in adults.
    Watkins RR; Lemonovich TL
    Am Fam Physician; 2011 Jun; 83(11):1299-306. PubMed ID: 21661712
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Macrolide therapy is associated with lower mortality in community-acquired bacteraemic pneumonia.
    Arnold FW; Lopardo G; Wiemken TL; Kelley R; Peyrani P; Mattingly WA; Feldman C; Gnoni M; Maurici R; Ramirez JA;
    Respir Med; 2018 Jul; 140():115-121. PubMed ID: 29957272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Community-acquired pneumonia: impact of empirical antibiotic therapy without respiratory fluoroquinolones nor third-generation cephalosporins.
    Pradelli J; Risso K; de Salvador FG; Cua E; Ruimy R; Roger PM
    Eur J Clin Microbiol Infect Dis; 2015 Mar; 34(3):511-8. PubMed ID: 25273975
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Doxycycline or moxifloxacin for the management of community-acquired pneumonia in the UK?
    Ludlam HA; Enoch DA
    Int J Antimicrob Agents; 2008 Aug; 32(2):101-5. PubMed ID: 18571380
    [TBL] [Abstract][Full Text] [Related]  

  • 37. High variability among Emergency Departments in 3rd-generation cephalosporins and fluoroquinolones use for community-acquired pneumonia.
    Batard E; Lecadet N; Goffinet N; Hardouin JB; ; Lepelletier D; Potel G; Montassier E
    Infection; 2015 Dec; 43(6):681-9. PubMed ID: 25998004
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prescription of antibiotics for adults hospitalized with community-acquired pneumonia in Korea in 2004: a population-based descriptive study.
    Yoon YK; Kim EJ; Chun BC; Eom JS; Park DW; Sohn JW; Kim MJ
    Respirology; 2012 Jan; 17(1):172-9. PubMed ID: 21995414
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness of antibiotic treatment strategies for community-acquired pneumonia: results from a cluster randomized cross-over trial.
    van Werkhoven CH; Postma DF; Mangen MJ; Oosterheert JJ; Bonten MJ;
    BMC Infect Dis; 2017 Jan; 17(1):52. PubMed ID: 28068956
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.